Performance-Enhancing Compounds Linked to Rare Spontaneous Splenic Rupture
Background
Atraumatic splenic rupture (ASR) is a rare, life-threatening surgical emergency typically occurring in spleens with underlying pathologies. While its causes are diverse, ranging from infections to malignancies, the specific link between ASR and the use of performance-enhancing compounds has been less documented, presenting a knowledge gap regarding potential drug-induced splenic vulnerabilities. This case report aims to shed light on this uncommon association.
Study Design
Results
Initially, embolization provided only transient stabilization for the patient, indicating the severity and progression of the splenic injury. Despite this intervention, the patient ultimately required an emergency laparotomy and total splenectomy to manage the acute, life-threatening condition. Histopathological examination of the removed spleen revealed large areas of splenic infarction (tissue death due to lack of blood supply), alongside features suggesting the possibility of an underlying vascular malformation. These findings indicate a severe and widespread splenic injury, potentially exacerbated or triggered by the patient's recent use of performance-enhancing compounds, although a direct causal link requires further investigation. The presence of infarction and potential malformation points to a compromised splenic state.
Why It Matters
This case report highlights a critical, rare, and potentially life-threatening complication associated with the use of performance-enhancing compounds. It underscores the importance for clinicians to consider ASR in patients presenting with acute abdominal pain who report using such substances, even in the absence of trauma. Increased awareness among healthcare providers is crucial for early diagnosis and intervention, potentially improving patient outcomes and preventing fatal complications. Future research, including larger observational studies or registries, is needed to establish a definitive causal link and identify specific compounds or usage patterns that elevate this risk.